Webcast scheduled for Monday, July 22 at 8:00
a.m. Eastern Time
CARLSBAD, Calif., July 8, 2024
/PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
announced today that it will host a live webcast on Monday, July 22nd at 8:00 a.m. Eastern Time to discuss results from
the Phase 1/2a HALOS study of ION582 for the treatment of people
with Angelman syndrome. Results from the HALOS study will also be
presented on Wednesday, July 24 at
the 2024 Angelman Syndrome Foundation (ASF) Family Conference and
Research Symposium in Sandusky,
Ohio.
The webcast may be accessed at
https://ir.ionis.com/events-and-presentations/upcoming-events. A
replay will be available for a limited time at the same
address.
About Ionis Pharmaceuticals, Inc.
For three decades,
Ionis has invented medicines that bring better futures to people
with serious diseases. Ionis currently has five marketed medicines
and a leading pipeline in neurology, cardiology, and other areas of
high patient need. As the pioneer in RNA-targeted medicines, Ionis
continues to drive innovation in RNA therapies in addition to
advancing new approaches in gene editing. A deep understanding of
disease biology and industry-leading technology propels our work,
coupled with a passion and urgency to deliver life-changing
advances for patients. To learn more about Ionis, visit Ionis.com
and follow us on X (Twitter) and LinkedIn.
Ionis Pharmaceuticals Investor Contact:
D.
Wade Walke, Ph.D. –
IR@ionis.com – 760-603-2331
Ionis Pharmaceuticals Media Contact:
Hayley Soffer – media@ionis.com –
760-603-4679
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ionis-announces-webcast-to-report-halos-study-results-for-ion582-in-angelman-syndrome-302189257.html
SOURCE Ionis Pharmaceuticals, Inc.